There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another
AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit
AbbVie has signed a deal worth up to $2.4 billion with the US biotech Harpoon Therapeutics, expanding a research and licensing collaboration involving technology that trains T-cells to targ
